T1D Trial Looks to Teach an Old Drug New Tricks

JDRF-funded clinical study of a drug called TUDCA looks to improve beta cell functioning in people recently diagnosed with T1D Until recently, much of type 1 diabetes (T1D) research has focused on suppressing the autoimmune system to prevent or reverse disease, but this approach has been slow to yield promising, long-term results in people with […]

Re-educating the Immune System in T1D

JDRF partner Selecta developed a novel technology for creating a T1D vaccine to potentially halt the disease process It has been more than 30 years since scientists identified the basic autoimmune feature of type 1 diabetes (T1D) when they discovered autoantibodies binding to targets from cells in the pancreas. And yet, devising therapies to halt […]

Unlocking a Combination Therapy for New Onset T1D

A new study is further assessing if a novel combination of drugs could help treat new onset type 1 diabetes University of Florida researchers are ready to launch a new clinical study to examine if a combination of two U.S Food and Drug Administration (FDA) approved drugs, antithymocyte globulin (ATG) and granulocyte colony stimulating factor […]

T1D Exercise Study – Participants Wanted!

Do you have type 1 diabetes? We are currently recruiting participants for an exercise intervention!!! The study will include group fitness classes at FITOLOGY and a series of tests before, during and after the intervention. The purpose of this study is to evaluate how exercise could improve blood sugar control of adults and adolescents with […]

Advancing a Key Artificial Pancreas Technology

Stable liquid glucagon developed by JDRF partner Xeris evaluated in first clinical study The JDRF Artificial Pancreas (AP) project is focused on accelerating the development of commercially-viable AP systems that better mimic the biological function of the pancreas and reduce the daily burden of managing type 1 diabetes (T1D). To achieve this goal, JDRF funds […]

JDRF FY2014 Annual Report Released

Thanks for making the 2013-2014 a great year for JDRF and the type one community in Central PA! Many exciting things have happened this year in T1D research, and the Central PA Chapter of JDRF raised $1.3 million to support this research. We couldn’t have done it without you! Check out the full Annual Report

Improving Beta Cell Health and Survival

JDRF-funded clinical study to test marketed drug to improve beta cell health and survival in T1D JDRF recently awarded a $2.1 million grant to Anath Shalev, M.D., director of the University of Alabama’s (UAB) Comprehensive Diabetes Center, to test the impact of a common blood pressure drug called verapamil on the health and survival of […]

Historic Progress for JDRF Encapsulation Research Program

First people with type 1 diabetes receive experimental encapsulated cell replacement therapies in clinical studies Two JDRF-funded partners have successfully implanted people with type 1 diabetes (T1D) with experimental encapsulated cell replacement therapies in clinical studies. These two programs are running in parallel and are evaluating two distinct encapsulation therapies. Encapsulated cell replacement therapy involves […]

It’s Time to Redefine Type 1 Diabetes

Last month, JDRF co-hosted a workshop where healthcare experts from government, nonprofit agencies and educational institutions discussed expanding the definition of Type 1 Diabetes (T1D) to recognize the earliest stages of human T1D before a person is clinically symptomatic. The benefits of the proposed system could include potentially faster drug development, identification of people living […]